ClinicalTrials.gg
CompletedNCT03381911Updated Jul 12, 2018

ECA vs E-Document Explanation

An interventional study of Embodied Conversational Agent in Literacy and Information Disclosure, sponsored by Boston Medical Center. Completed at 1 site in United States. Open to participants aged 21 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2018-07-12.

Sponsored by Boston Medical Center · Not applicable, Interventional, and Health services research

Phase
Not applicable
Study type
Interventional
Enrollment
35
Allocation
Randomized
Ages
21 Years and older
Sex
All
01

Study summary

This study will investigate how consent forms and other health care documents are explained to patients. The findings will be used to create a computer program that can successfully explain consent and other health-related forms to individuals who have difficulty reading and understanding consent forms on their own as a supplement to the normal consent process done in research settings.

In a prior study, the investigators delivered a similar protocol, where subjects were first consented and then given a mock consent form (administered in 1 of 3 arms: RA, ECA, or ECA + RA). Subjects in this protocol struggled with the concept of a "mock" consent process, especially after they had just completed a consent process for the study itself. The current protocol, using deception research methods, aims to provide a more pure assessment of ECA consent vs the standard (here, E-consent) by waiving consent and delivering the sham consent as if it were reality. In the context of a protocol that employs deception methods, participants in the current study would be invited as healthy volunteers, and be randomized to 1 of 2 different consent processes to evaluate the relative benefits of different approaches for informed consent. After the knowledge tests have been completed, subjects will undergo a debriefing where they are made fully aware of the deception and its purpose. At that time, subjects will also be given the opportunity to "opt out" and not have their data included in the study results.

Read the detailed description

Participants who call in response to the clinic flyers will first confirm eligibility criteria of age (≥21) and language (able to complete a study visit in English). Once eligibility is confirmed, participants will be scheduled to come to BMC for a single study visit that will take approximately 60-90 minutes. Randomization to one study arm or the other will occur when subject arrives for appointment.

The following activities will occur at a single study visit:

  1. administer sham consent (via e-consent or ECA per randomization result)
  2. knowledge test
  3. data collection

    1. socio-demographics
    2. health literacy assessment (REALM)
    3. ECA satisfaction (for ECA arm subjects only)
    4. Emotional connection (adapted PROMIS) (for ECA arm subjects only)
  4. Debriefing

    1. Describe true study aims
    2. Opt out option (subject can request that their data not be used)
02

Conditions studied

  • Literacy
  • Information Disclosure

Browse trials for

03

In context

Literacy

201 studies on the registry are indexed under Literacy; 69 are open to participants now.

This study's enrollment of 35 is below the median of 124 across 170 interventional studies indexed under Literacy.

Browse Literacy studies →

Lead sponsor

Boston Medical Center is the lead sponsor of 323 studies on the registry; 33 are open to participants now.

Of its 34 completed or terminated interventional studies of FDA-regulated products, 28 (82%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
21 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • English speaking
  • able to come in for a single study visit

Exclusion criteria

Exclusion Criteria:

  • Deaf
  • Blind
05

Study design

Phase
Not applicable
Primary purpose
Health services research
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
35 participants (actual)

Study arms

  • No intervention
    E-Consent

    This arm is the standard of care, where the consent form is presented to the subject on a computer screen and he/she can scroll ahead and back as needed. There is also an option to have each screen read aloud.

  • Experimental
    ECA Consent

    In this arm an Embodied Conversational Agent (ECA) which is a computer generated character reads the consent form aloud to the subject, and also describes each section using a pre-loaded script. In addition, the character performs "teach-back", where she asks the subject a question about the section that was just described, and then repeats the section if the question is answered incorrectly.

    Other: Embodied Conversational Agent

Interventions

  • OtherEmbodied Conversational Agent

    The Embodied Conversational Agent (ECA) is a computer generated character that can interact with study subjects through a touch screen computer. The ECA is programmed to respond with relevant speech and body language to a subject's responses.

06

What researchers measure

Primary outcomes

  1. Knowledge of informed consent document

    A knowledge test will be given to assess the subjects' level of comprehension of the informed consent form

    Time frame: immediately following the study interview

Secondary outcomes

  1. Survey of level of satisfaction with the ECA

    For subjects in the ECA study arm, satisfaction with the agent will be assessed

    Time frame: immediately following the study interview

  2. Amount of time spent on consent process

    The amount of time that the subject spent with the consent form, assessed in both arms

    Time frame: immediately following the study interview

07

Study locations

1 site
  • Boston Medical Center
    Boston, Massachusetts 02118, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2018 to primary completion in Apr 2018, 3 months.

Of 115 non-industry interventional studies with no phase under Literacy, half reached primary completion within 11 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 20. This study's 3 months is below that.

Counting every sponsor, half of 117 studies reached it within 11 months; a quarter within 4 and three quarters within 19.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 6, 2017
First posted
Dec 22, 2017
StartActual
Jan 4, 2018
Primary completionActual
Apr 18, 2018
CompletionActual
Apr 18, 2018
Last update
Jul 12, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 12, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03381911
Collaborators
Northeastern University, National Cancer Institute (NCI)
Responsible party
Michael Paasche-Orlow (Professor, Dept General Internal Medicine, BUSM, Boston Medical Center) — Principal investigator
First posted
Dec 22, 2017
Start date
Jan 4, 2018
Primary completion
Apr 18, 2018
Completion
Apr 18, 2018
Last update
Jul 12, 2018

Study contacts

Michael Paasche-Orlow, MD, MPH
principal investigator · Boston Medical Center

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion